Replimune Group, Inc.
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Last report1 of 8 at or beyond impliedshaded = implied▲▼ = realized× = |realized| ÷ implied
Replimune Group, Inc.
17.60
+23.07%
vs ±9.9% implied · ×2.32
shaded = implied · ▲▼ = realized
Replimune has 6 disclosed suppliers and 0 disclosed customers in SEC filings.
SentenceIn connection with the Settlement Agreement, we entered into a License and Covenant Agreement with Amgen in which we agreed to pay Amgen low single-digit royalty payments on net sales of our products that, but for the license, could be found to infringe a valid Amgen patent on a country-by-country and product-by-product basis.
SentenceWe have entered into agreements with BMS for the supply of nivolumab, its anti-PD-1 therapy, for use in connection with our ongoing IGNYTE Phase 1/2 trials with RP1, our Phase 1/2 clinical trial with RP2 and our Phase 1 and Phase 2 clinical trials with RP3 where we decide to use nivolumab.
SentenceAdditionally, our signal finding study in HCC is being developed in combination with atezolizumab and bevacizumb under a supply and clinical collaboration agreement with Roche.
REPL 10-Kaccession 0001628280-26-045886
SentenceIn March 2023, the FDIC took control of Silicon Valley Bank, or SVB, where we previously held a portion of our cash.
REPL 10-Kaccession 0001628280-26-045886
SentenceWe participate, through our subsidiary in the United Kingdom, in the research and development program provided by the United Kingdom tax relief program, such that a percentage of up to 16.2% of our qualifying research and development expenditures are reimbursed by the United Kingdom government, and such incentives are reflected as other income.
REPL 10-Kaccession 0001628280-26-045886
—
Linked news
Expected move
Inputsspot 17.61exp Feb 19ATM strike 18ATM straddle 6.35IV 82%